Numerous studies document significant improvement in motor symptoms in patients with Parkinson's disease (PD) after deep brain stimulation of the subthalamic nucleus (STN-DBS). However, little is known about the initial effects of STN-DBS on nonmotor domains.Our objective was to elucidate the initial effects of STN-DBS on non-motor and motor symptoms in PD patients in a 4-month follow-up.This open prospective study followed 24 patients with PD who underwent STN-DBS. The patients were examined using dedicated rating scales preoperatively and at 1 and 4 months following STN-DBS to determine initial changes in motor and nonmotor symptoms. Patients at month 1 after STN-DBS had significantly reduced the Parkinson's disease Questionnaire scores (P = .018) and Scales for Outcomes in Parkinson's disease - Autonomic scores (P = .002); these scores had increased at Month 4 after DBS-STN. Nonmotor Symptoms Scale for Parkinson's Disease had improved significantly at Month 1 (P < .001); at Month 4, it remained significantly lower than before stimulation (P = .036). There was no significant difference in The Parkinson's Disease Sleep Scaleat Month 1 and significant improvement at Month 4 (P = .026). There were no significant changes in The Female Sexual Function Index or International Index of Erectile Function. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III scores show significant improvements at Month 1 (P < .001) and at Month 4 (P < .001).STN-DBS in patients with advanced PD clearly improves not only motor symptoms, but also several domains of nonmotor functions, namely sleep, autonomic functions and quality of life quickly following the start of stimulation.

Department of Neurology Department of Neurosurgery University Hospital and Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic Clinic of Neurology Jessenius Faculty of Medicine in Martin Comenius University in Bratislava and University Hospital in Martin Slovak Republic Department of Biostatistics Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Faggiani E, Benazzouz A. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: from history to the interaction with the monoaminergic systems. Prog Neurobiol 2016;151:139–56. PubMed

Timmermann L, Jain R, Chen L, et al. Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson's disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study. Lancet Neurol 2015;14:693–701. PubMed

Sauerbier A, Ray Chaudhuri K. Non-motor symptoms: the core of multi-morbid Parkinson's disease. Br J Hosp Med 2014;75:18–24. PubMed

Noyce AJ, Lees AJ, Schrag AE. The prediagnostic phase of Parkinson's disease. J Neurol Neurosurg Psychiatry 2016;87:871–8. PubMed PMC

Pfeiffer RF. Non-motorsymptoms in Parkinson's disease. Parkinsonism Relat Disord 2016;22:119–22. PubMed

Cury RG, Galhardoni R, Teixeira MJ, et al. Subthalamic deep brain stimulation modulates conscious perception of sensory function in Parkinson's disease. Pain 2016;157:2758–65. PubMed

Ineichen C, Baumann-Vogel H, Christen M. Deep brain stimulation: in search of reliable instruments for assessing complex personality-related changes. Brain Sci 2016;6:E40. PubMed PMC

Nassery A, Palmese CA, Sarva H, et al. Psychiatric and cognitive effects of deep brain stimulation for parkinson's disease. Curr Neurol Neurosci Rep 2016;16:87. PubMed

Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2012;18:994–7. PubMed

Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society—sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–70. PubMed

Fahn S, Elton RL. Fahn S, Marsden CD, Goldstein M. UPDRS program members. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. 153–63.

Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric propertiesof a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 2007;22:1901–11. PubMed

Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241–8. PubMed

Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353–7. PubMed

Visser M, Marinus J, Stiggerlbout AM, et al. Assessment of autonomic dysfunctions in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306–12. PubMed

Chaudhuri KR, Pal S, DiMarco A, et al. Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629–35. PubMed PMC

Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30. PubMed

Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208. PubMed

Christenson GA, Faber RJ, de Zwaan M, et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994;55:5–11. PubMed

Chou KL, Taylor JL, Patil PG. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson's disease. Parkinonism Relat Disord 2016;19:966–9. PubMed PMC

Merlino G, Lettieri C, Mondani M, et al. Microsubthalamotomy improves sleep in patients affected by advanced Parkinson's disease. Sleep Med 2014;15:637–41. PubMed

Keitel A, Wojtecki L, Hirschmann J, et al. Motor and cognitive placebo-nocebo-responses in Parkinson's disease patients with deep brain stimulation. Behav Brain Res 2013;250:199–205. PubMed

Dafsari HS, Reddy P, Herchenbach C, et al. IPMDS Non-Motor Symptoms Study Group. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson's disease. Brain Stimul 2016;9:78–85. PubMed

Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:742–5. PubMed PMC

Halim A, Baumgartner L, Binder DK. Effect of deep brain stimulation on autonomic dysfunction in patients with Parkinson's disease. J Clin Neurosci 2011;18:804–6. PubMed

Basiago A, Binder DK. Effects of deep brain stimulation on autonomic function. Brain Sci 2016;6:E33. PubMed PMC

Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009;24:635–6. PubMed PMC

Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, et al. Longitudinal Parkinson's Disease Patient Study, Estudio Longitudinal de Pacients con Enfermedad da Parkinson Group. Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT). Neur J Neurol 2010;17:194–201. PubMed

Eugster L, Bargiotas P, Bassetti CL, et al. Deep brain stimulation and sleep-wake functions in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2016;32:12–9. PubMed

Kanovský P, Kubová D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17:188–91. PubMed

Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord 2006;21:727–8. PubMed

Tykocki T, Mandat T, Nauman P. Influence of subthalamic deep brain stimulation on dysautonomia observed in Parkinson's disease. Neurol Neurochir Pol 2010;44:277–84. PubMed

Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004;75:1260–4. PubMed PMC

Pohanka M, Kanovský P, Bares M, et al. Pergolidemesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol 2004;11:483–8. PubMed

Merola A, Romagnolo A, Rizzi L, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol 2017;264:40–8. PubMed

Dafsari HS, Reker P, Stalinski L, et al. EUROPAR and the IPMDS (International Parkinson's and Movement Disorders Society) Non-Motor Parkinson's Disease Study Group. Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age. Mov Disord 2017;33:99–107. PubMed

Deep brain stimulation electrode position impact on parkinsonian non-motor symptoms